Business Wire

On 3 rd April 2025, MultiBank Group Delivers a Further Substantial Milestone by Achieving an Unprecedented Trading Volume of $55.85 Billion.

9.4.2025 10:32:00 CEST | Business Wire | Press Release

Share

MultiBank Group, the world’s largest financial derivatives institution based in Dubai, is proud to announce a historic milestone—on April 3, 2025, the Group recorded its highest ever single day trading volume, surpassing USD 55.85 billion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250409783912/en/

MultiBank Group recorded its highest ever single day trading volume, surpassing USD 55.85 billion.

This record-breaking achievement marks a strong start to the second quarter for the group, with an impressive unparalleled average daily trading volume of over USD 35 billion during the first four trading days of April.

This unprecedented milestone reflects the strong confidence a diverse global clientele, including individual traders and institutional investors, has placed in the firm. The performance confirms the Group’s focus on transparency, robust security measures, and rigorous regulatory compliance.

Commenting on this breakthrough, Founder and Chairman Naser Taher said: “We are pleased to share these impressive figures with our valued clients and business partners. It displays our financial strength, our drive for technological progress, and the trust our customers place in us.”

Throughout 2024, MultiBank Group witnessed remarkable growth, marked by increased revenue resulting from international expansions and new product rollouts. Among the most notable innovations was the debut of MultiBank-Plus, a next-generation platform and app designed to deliver a seamless trading experience. The company further enhanced its position in the digital asset arena with the launch of the MultiBank.io Crypto Exchange App, setting new benchmarks for operational efficiency around cryptocurrencies. Additionally, MEX Exchange, the first global ECN tool tailored for the BRICS and GCC regions, brought unmatched liquidity and advanced capabilities to a rapidly growing industry.

Strategic partnerships have played a pivotal role in bolstering MultiBank Group’s presence. Collaborations with Al Ansari Exchange and Mashreq Bank streamlined transactions, offering users faster and more convenient deposit and withdrawal solutions. The Group also secured Dubai’s prestigious Virtual Asset Service Provider (VASP) license, highlighting its commitment to stringent governance standards and dedication to excellence.

Building on this momentum, the organization delivered outstanding financial results for 2024, with revenue surpassing $361 million and net income exceeding $264 million, reflecting 16% growth.

Established in California in 2005, MultiBank Group offers financial services to more than two million clients in over 100 nations. With licenses from 17 reputable global regulatory bodies, the company continues to prioritize exceptional service and continuous innovation in markets.

ABOUT MULTIBANK GROUP

MultiBank Group, established in California, USA in 2005, is a global leader in financial derivatives, serving over 2 million clients across 100 countries, and boasts a trading volume that exceeds $35 billion per day during the first 4 days in April 2025. Renowned for its innovative trading solutions, robust regulatory compliance, and exceptional customer service, the Group offers an array of brokerage services and asset management solutions. It is regulated across five continents by 17 of the most reputable financial authorities globally. The Group’s award-winning trading platforms offer up to 500:1 leverage on a diverse range of products, including Forex, Metals, Shares, Commodities, Indices, and Cryptocurrencies. MultiBank Group has received over 70 financial awards recognizing its trading excellence and regulatory compliance. For more information, visit MultiBank Group’s website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250409783912/en/

Contacts

mohammad.shakfeh@multibankfx.com
00971585754191

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye